CA2907570A1 - Protocol for identifying and isolating antigen-specific b cells and producing antibodies to desired antigens - Google Patents

Protocol for identifying and isolating antigen-specific b cells and producing antibodies to desired antigens

Info

Publication number
CA2907570A1
CA2907570A1 CA2907570A CA2907570A CA2907570A1 CA 2907570 A1 CA2907570 A1 CA 2907570A1 CA 2907570 A CA2907570 A CA 2907570A CA 2907570 A CA2907570 A CA 2907570A CA 2907570 A1 CA2907570 A1 CA 2907570A1
Authority
CA
Canada
Prior art keywords
cells
antigen
specific
cell
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2907570A
Other languages
English (en)
French (fr)
Inventor
Daniel S. Allison
Benjamin H. Dutzar
Leon F. Garcia-Martinez
Katie ANDERSON
Ethan W. Ojala
John A. Latham
Jens Billgren
Anne Elisabeth Carvalho Jensen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
Alder Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alder Biopharmaceuticals Inc filed Critical Alder Biopharmaceuticals Inc
Publication of CA2907570A1 publication Critical patent/CA2907570A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/5052—Cells of the immune system involving B-cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Dispersion Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
CA2907570A 2013-03-15 2014-03-18 Protocol for identifying and isolating antigen-specific b cells and producing antibodies to desired antigens Abandoned CA2907570A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361791755P 2013-03-15 2013-03-15
US61/791,755 2013-03-15
PCT/US2014/030994 WO2014146074A2 (en) 2013-03-15 2014-03-18 Protocol for identifying and isolating antigen-specific b cells and producing antibodies to desired antigens

Publications (1)

Publication Number Publication Date
CA2907570A1 true CA2907570A1 (en) 2014-09-18

Family

ID=51538609

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2907570A Abandoned CA2907570A1 (en) 2013-03-15 2014-03-18 Protocol for identifying and isolating antigen-specific b cells and producing antibodies to desired antigens

Country Status (8)

Country Link
US (2) US20140287952A1 (https=)
EP (1) EP2972330A4 (https=)
JP (1) JP6466397B2 (https=)
KR (1) KR20150140679A (https=)
AU (1) AU2014232225B2 (https=)
CA (1) CA2907570A1 (https=)
IL (1) IL241433B (https=)
WO (1) WO2014146074A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
GB201316644D0 (en) 2013-09-19 2013-11-06 Kymab Ltd Expression vector production & High-Throughput cell screening
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
PE20161439A1 (es) 2014-03-21 2017-01-26 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos
EP3835319B1 (en) 2014-12-19 2025-11-19 H. Lundbeck A/S Humanized anti-acth antibodies and use thereof
WO2016149137A1 (en) * 2015-03-18 2016-09-22 Epitomics, Inc. High throughput monoclonal antibody generation by b cell panning and proliferation
WO2017147508A1 (en) * 2016-02-26 2017-08-31 Sri International Identification and isolation of antibodies from white blood cells
EP3426288A4 (en) 2016-04-15 2019-10-30 Alder Biopharmaceuticals, Inc. ANTI-PACAP ANTIBODIES AND USES THEREOF
WO2018055574A1 (en) 2016-09-23 2018-03-29 Teva Pharmaceuticals International Gmbh Treating refractory migraine
MA46959A (fr) 2016-12-02 2019-10-09 Juno Therapeutics Inc Cellules b modifiées et compositions et méthodes associées
US20180299436A1 (en) * 2017-01-20 2018-10-18 Shenzhen New Industries Biomedical Engineering Co., Ltd. A method, kit and system for preparing an antibody pair and the use of the kit
US11125757B2 (en) * 2017-05-26 2021-09-21 Emory University Methods of culturing and characterizing antibody secreting cells
CN107058235B (zh) * 2017-06-05 2020-08-11 深圳大学 一种b细胞筛选方法及其在单克隆抗体制备中的应用
WO2020242856A1 (en) * 2019-05-31 2020-12-03 The Penn State Research Foundation Specific selection of immune cells using versatile display scaffolds
CN115298323A (zh) * 2020-01-17 2022-11-04 嘉普科德基因组学公司 靶向测序方法
CN114441752B (zh) * 2020-11-03 2024-11-26 中国科学院苏州纳米技术与纳米仿生研究所 一种筛选方法
EP4288450A1 (en) * 2021-02-05 2023-12-13 Amgen Inc. Enhanced hybridoma generation
CN115166241B (zh) * 2022-08-22 2023-03-24 广东忠信生物科技有限公司 一种同时筛选记忆b细胞和浆细胞的高效筛选技术及应用
WO2025240335A1 (en) 2024-05-13 2025-11-20 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990000625A1 (en) * 1988-07-14 1990-01-25 Monoclonetics International, Inc. Pre-screening for depletion and enrichment of specific b-cells
EP0542810A1 (en) 1990-08-02 1993-05-26 B.R. Centre Limited Methods for the production of proteins with a desired function
ES2103770T3 (es) * 1990-11-26 1997-10-01 Akzo Nobel Nv Procedimiento de produccion de anticuerpos monoclonales.
US5213960A (en) * 1992-03-09 1993-05-25 Tanox Biosystems, Inc. Methods for selecting low frequency antigen-specific single B lymphocytes
US5256542A (en) * 1992-03-09 1993-10-26 Tanox Biosystems, Inc. Selecting low frequency antigen-specific single B lymphocytes with correction for background noise
US20050287607A1 (en) * 2004-01-07 2005-12-29 Diamond Betty A Methods and compositions for identification of antigen-specific B cell populations
US20060051348A1 (en) 2004-09-09 2006-03-09 Jorn Gorlach Method of producing a plurality of isolated antibodies to a plurality of cognate antigens
WO2007001420A2 (en) * 2004-10-22 2007-01-04 Genencor International, Inc. Isolating human antibodies
WO2007046757A1 (en) * 2005-10-17 2007-04-26 Gambro Lundia Ab Extracorporeal blood cleaning
DK2021463T3 (en) * 2006-05-19 2017-01-16 Alder Biopharmaceuticals Inc Culture method to obtain a cloned population of antigen-specific B cells
WO2008073166A2 (en) * 2006-08-23 2008-06-19 Xcellerex, Inc. Multi-variant cell indication technique
PT2121920E (pt) * 2007-03-01 2011-10-03 Symphogen As Método de clonagem de anticorpos cognatos
CA3023900A1 (en) * 2007-12-27 2009-07-09 Abbott Laboratories Anti-t. cruzi antibodies and methods of use
PL2400298T3 (pl) * 2010-05-28 2014-01-31 Hoffmann La Roche Sposób hodowania pojedynczych komórek b oraz wytwarzania swoistych przeciwciał
MX2013009859A (es) * 2011-03-01 2014-02-28 Novo Nordisk As Ligandos dr3 antagonicos.
CN103946236B (zh) * 2011-11-23 2018-02-16 弗·哈夫曼-拉罗切有限公司 表达cd40l的哺乳动物细胞及其用途
US20150110802A1 (en) * 2012-02-29 2015-04-23 Medlmmune, Llc Antibody production methods

Also Published As

Publication number Publication date
EP2972330A2 (en) 2016-01-20
AU2014232225A1 (en) 2015-09-03
JP6466397B2 (ja) 2019-02-06
IL241433B (en) 2019-12-31
US20160033504A1 (en) 2016-02-04
WO2014146074A3 (en) 2014-11-06
JP2016512044A (ja) 2016-04-25
US20140287952A1 (en) 2014-09-25
AU2014232225B2 (en) 2020-03-19
WO2014146074A2 (en) 2014-09-18
EP2972330A4 (en) 2016-10-26
IL241433A0 (en) 2015-11-30
KR20150140679A (ko) 2015-12-16

Similar Documents

Publication Publication Date Title
AU2014232225B2 (en) Protocol for identifying and isolating antigen-specific B cells and producing antibodies to desired antigens
AU2007307324B2 (en) Culture method for obtaining a clonal population of antigen-specific B cells
US20100034807A1 (en) Methods and compositions for discovery of target-specific antibodies using antibody repertoire array (ara)
EP2724157B1 (en) Method for screening cells
US10934524B2 (en) High throughput monoclonal antibody generation by B cell panning and proliferation
JP6978516B2 (ja) 胸腺細胞上清を産生するための方法
JP2019509729A (ja) 抗体産生のためにｂ細胞を拡張及び分化する方法
CN102863529A (zh) 一种vegf单抗及包含该单抗的骨折愈合评价抗体芯片
JP2018148832A (ja) モノクローナル抗体の製造方法及び製造装置
CN121005774A (zh) 小鼠肝炎病毒抗体及其应用
HK1127372B (en) Culture method for obtaining a clonal population of antigen-specific b cells
HK1127372A (en) Culture method for obtaining a clonal population of antigen-specific b cells
AYYAR et al. Production and Use of
CN116514962A (zh) 特异性结合n蛋白的抗体或其功能性片段及其用途

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190315

FZDE Discontinued

Effective date: 20220601